Clinical presentations and outcomes of young women aged & lt;40 yrs with Ductal carcinoma in situ
CONCLUSION: Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.PMID:37807772 | DOI:10.3233/BD-230018 (Source: Breast Disease)
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Zhiyan Yan Joanne Ngeow John Allen Geok Hoon Lim Source Type: research
Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study
Breast Dis. 2023;42(1):305-313. doi: 10.3233/BD-230025.ABSTRACTBreast cancer is the most incidental and deadly neoplasm worldwide; in Mexico, very few epidemiologic reports have analyzed the pathological features and its impact on their clinical outcome. Here, we studied the relation between pathological features and the clinical presentation at diagnosis and their impact on the overall and progression-free survival of patients with breast cancer. For this purpose, we collected 199 clinical records of female patients, aged at least 18 years old (y/o), with breast cancer diagnosis confirmed by biopsy. We excluded patients w...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Anna Gozalishvilli-Boncheva Iv án R Gonzalez-Espinoza Abraham Castro-Ponce Omar A Bravo-Guti érrez Gabriela Ju árez-Salazar Ricardo I Montes-de-Oca-Moreda Evelyn Aguirre-Flores Marisela Coyotl-Huexotl Juan Orozco-Luis Mariana Chiquillo-Dom ínguez Juli Source Type: research
A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases
Breast Dis. 2023;42(1):315-318. doi: 10.3233/BD-230039.ABSTRACTER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal d...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Smita Chandra Sanya Bhasin Sunil Saini Source Type: research
Clinical presentations and outcomes of young women aged & lt;40 yrs with Ductal carcinoma in situ
CONCLUSION: Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.PMID:37807772 | DOI:10.3233/BD-230018 (Source: Breast Disease)
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Zhiyan Yan Joanne Ngeow John Allen Geok Hoon Lim Source Type: research
Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study
Breast Dis. 2023;42(1):305-313. doi: 10.3233/BD-230025.ABSTRACTBreast cancer is the most incidental and deadly neoplasm worldwide; in Mexico, very few epidemiologic reports have analyzed the pathological features and its impact on their clinical outcome. Here, we studied the relation between pathological features and the clinical presentation at diagnosis and their impact on the overall and progression-free survival of patients with breast cancer. For this purpose, we collected 199 clinical records of female patients, aged at least 18 years old (y/o), with breast cancer diagnosis confirmed by biopsy. We excluded patients w...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Anna Gozalishvilli-Boncheva Iv án R Gonzalez-Espinoza Abraham Castro-Ponce Omar A Bravo-Guti érrez Gabriela Ju árez-Salazar Ricardo I Montes-de-Oca-Moreda Evelyn Aguirre-Flores Marisela Coyotl-Huexotl Juan Orozco-Luis Mariana Chiquillo-Dom ínguez Juli Source Type: research
A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases
Breast Dis. 2023;42(1):315-318. doi: 10.3233/BD-230039.ABSTRACTER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal d...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Smita Chandra Sanya Bhasin Sunil Saini Source Type: research
Clinical presentations and outcomes of young women aged & lt;40 yrs with Ductal carcinoma in situ
CONCLUSION: Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.PMID:37807772 | DOI:10.3233/BD-230018 (Source: Breast Disease)
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Zhiyan Yan Joanne Ngeow John Allen Geok Hoon Lim Source Type: research
Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study
Breast Dis. 2023;42(1):305-313. doi: 10.3233/BD-230025.ABSTRACTBreast cancer is the most incidental and deadly neoplasm worldwide; in Mexico, very few epidemiologic reports have analyzed the pathological features and its impact on their clinical outcome. Here, we studied the relation between pathological features and the clinical presentation at diagnosis and their impact on the overall and progression-free survival of patients with breast cancer. For this purpose, we collected 199 clinical records of female patients, aged at least 18 years old (y/o), with breast cancer diagnosis confirmed by biopsy. We excluded patients w...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Anna Gozalishvilli-Boncheva Iv án R Gonzalez-Espinoza Abraham Castro-Ponce Omar A Bravo-Guti érrez Gabriela Ju árez-Salazar Ricardo I Montes-de-Oca-Moreda Evelyn Aguirre-Flores Marisela Coyotl-Huexotl Juan Orozco-Luis Mariana Chiquillo-Dom ínguez Juli Source Type: research
A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases
Breast Dis. 2023;42(1):315-318. doi: 10.3233/BD-230039.ABSTRACTER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal d...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Smita Chandra Sanya Bhasin Sunil Saini Source Type: research
Clinical presentations and outcomes of young women aged & lt;40 yrs with Ductal carcinoma in situ
CONCLUSION: Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.PMID:37807772 | DOI:10.3233/BD-230018 (Source: Breast Disease)
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Zhiyan Yan Joanne Ngeow John Allen Geok Hoon Lim Source Type: research
Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study
Breast Dis. 2023;42(1):305-313. doi: 10.3233/BD-230025.ABSTRACTBreast cancer is the most incidental and deadly neoplasm worldwide; in Mexico, very few epidemiologic reports have analyzed the pathological features and its impact on their clinical outcome. Here, we studied the relation between pathological features and the clinical presentation at diagnosis and their impact on the overall and progression-free survival of patients with breast cancer. For this purpose, we collected 199 clinical records of female patients, aged at least 18 years old (y/o), with breast cancer diagnosis confirmed by biopsy. We excluded patients w...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Anna Gozalishvilli-Boncheva Iv án R Gonzalez-Espinoza Abraham Castro-Ponce Omar A Bravo-Guti érrez Gabriela Ju árez-Salazar Ricardo I Montes-de-Oca-Moreda Evelyn Aguirre-Flores Marisela Coyotl-Huexotl Juan Orozco-Luis Mariana Chiquillo-Dom ínguez Juli Source Type: research
A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases
Breast Dis. 2023;42(1):315-318. doi: 10.3233/BD-230039.ABSTRACTER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal d...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Smita Chandra Sanya Bhasin Sunil Saini Source Type: research
Clinical presentations and outcomes of young women aged & lt;40 yrs with Ductal carcinoma in situ
CONCLUSION: Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.PMID:37807772 | DOI:10.3233/BD-230018 (Source: Breast Disease)
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Zhiyan Yan Joanne Ngeow John Allen Geok Hoon Lim Source Type: research
Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study
Breast Dis. 2023;42(1):305-313. doi: 10.3233/BD-230025.ABSTRACTBreast cancer is the most incidental and deadly neoplasm worldwide; in Mexico, very few epidemiologic reports have analyzed the pathological features and its impact on their clinical outcome. Here, we studied the relation between pathological features and the clinical presentation at diagnosis and their impact on the overall and progression-free survival of patients with breast cancer. For this purpose, we collected 199 clinical records of female patients, aged at least 18 years old (y/o), with breast cancer diagnosis confirmed by biopsy. We excluded patients w...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Anna Gozalishvilli-Boncheva Iv án R Gonzalez-Espinoza Abraham Castro-Ponce Omar A Bravo-Guti érrez Gabriela Ju árez-Salazar Ricardo I Montes-de-Oca-Moreda Evelyn Aguirre-Flores Marisela Coyotl-Huexotl Juan Orozco-Luis Mariana Chiquillo-Dom ínguez Juli Source Type: research
A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases
Breast Dis. 2023;42(1):315-318. doi: 10.3233/BD-230039.ABSTRACTER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal d...
Source: Breast Disease - October 9, 2023 Category: Cancer & Oncology Authors: Smita Chandra Sanya Bhasin Sunil Saini Source Type: research
